Dr. Steve Perrin Biography

Steve is currently the Chief Executive Officer and Chief Scientific Officer at the ALS Therapy Development Institute in Cambridge MA. He earned his Ph.D. at Boston University Medical Center studying the transcriptional regulation of genes during adipocyte and myocyte differentiation.
Dr. Perrin moved into the pharmaceutical industry in 1997 holding positions at the Hoechst-Ariad Genomics Center Aventis Pharmaceuticals and more recently as Director of Molecular Profiling at Biogen.
Dr. Perrin joined the ALS Therapy Development Institute in 2007 as part of historical collaboration between the Muscular Dystrophy Association Augie’s Quest and the Institute to develop effective therapeutics for people with ALS. He spearheaded the development of computational biology capabilities and information management systems to more clearly understand the molecular mechanisms associated with disease onset and progression in neurodegenerative diseases and expanded the drug screening program to include expertise in the generation and assessment of gene therapy vectors and protein biologics in preclinical models of neurodegeneration. This has led to the identification of multiple clinical candidates including antiCD40L (2009) and fingolimod (2012).

As a renowned expert and highly sought-after speaker, Dr. Steve Perrin's expertise is in high demand. To book Dr. Steve Perrin for your next event, conference, or workshop, please contact our speaker booking agency. Our experienced team will work closely with you to understand your specific needs and help secure Dr. Steve Perrin's participation. With our professional guidance and seamless booking process, you can ensure a memorable and impactful experience for your audience. Don't miss the opportunity to engage your audience with Dr. Steve Perrin's compelling insights and inspire positive change within your organization. Fill out the booking request form to take the first step in securing Dr. Steve Perrin for your next speaking engagement.